NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

AMGN - Amgen Inc

Amgen Inc. (Amgen), incorporated in 1980, is an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. As of December 31, 2010, the Company marketed primarily recombinant protein therapeutics in supportive cancer care, nephrology a","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# AMGNhart

Amgen Inc News


ETFs: How To Ride The Surge In Biotech M&A (XBI, IBB, PBE, PFE, CELG, AMGN ...
ETF Daily News - 31 minutes ago
Don Miller: Innovations in biotechnology are evolving at the speed of light. In fact, astonishing advancements in biotech have transformed the way we practice medicine.
The Definitive Biotech ETF Guide (IBB, XBI, FBT) - NASDAQ

Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen ...
StreetInsider.com (subscription) - May 21, 2012
Shares of Affymax, Inc. (NASDAQ: AFFY) are up a sharp 7.3 percent Monday, potentially on the heels of a raised price target from McNicoll Lewis & Vlak's Ed Arce earlier.

Medgenics Moving In Record Time
Seeking Alpha - May 21, 2012
Medgenics (MDGN) scores again. After a season of good news, the company recently told investors that in record time, the FDA approved its filing to start clinical trials using its Biopump platform technology to treat anemia in kidney dialysis patients.

Investment Choices For Melanoma Awareness Month
Seeking Alpha - May 21, 2012
Affecting more than 65000 new patients and claiming about 11000 lives annually, melanoma treatment represents a huge unmet need. With the knowledge that sun exposure is responsible for the cause of about two-thirds of all melanoma cases, ...

72% complete response in Ph II leukemia study of Amgen's blinatumomab
The Pharma Letter - May 21, 2012
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced updated results from a Phase II study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72% of adult ...

Melanoma Awareness Month Investment Opportunities: AMGN, ONCS, PVCT
Market Playground - May 18, 2012
By Amy Baldwin May is officially melanoma awareness month. Affecting more than 65000 new patients and claiming about 11000 lives annually, melanoma treatment represents a huge unmet need.

Notable ETF Inflow Detected - TQQQ, ALXN, ALTR, AMGN
TheStreet.com - May 18, 2012
By Forbes 05/18/12 - 10:50 AM EDT By ETFChannel.com "We need a high price for it to work, but not uncomfortably so -- because that would be a deal hijacked by a frenzied public.

Notable ETF Inflow Detected - TQQQ, ALXN, ALTR, AMGN
Forbes - May 18, 2012
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Proshares UltraPro QQQ (NASD: TQQQ) where we have detected an approximate $89.6 million dollar inflow - that's a 100.0% ...

Playoff Trifecta Means Windfall Curbed by LA Traffic
BusinessWeek - May 18, 2012
By James Nash and Mason Levinson on May 18, 2012 Los Angeles hosts three playoff series this weekend, a boon for downtown's Staples Center and a preview of the potential traffic gridlock that a proposed football stadium would add to the mix.

Amgen Says BiTE Antibody Blinatumomab Achieved High Rate Of Complete Response
RTT News - May 16, 2012
(RTTNews) - Amgen Inc. (AMGN: News ) announced updated results from a Phase 2 study that showed treatment with blinatumomab or AMG 103 helped achieve a high-rate of complete response or CR in 72 percent of adult patients with relapsed or refractory ...
Amgen's BiTEĀ® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete ... - MarketWatch (press release)

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>